中山醫學大學機構典藏 CSMUIR:Item 310902500/24865
English  |  正體中文  |  简体中文  |  全文笔数/总笔数 : 17918/22933 (78%)
造访人次 : 7437678      在线人数 : 60
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜寻范围 查询小技巧：
  • 您可在西文检索词汇前后加上"双引号"，以获取较精准的检索结果
  • 若欲以作者姓名搜寻，建议至进阶搜寻限定作者字段，可获得较完整数据
    •  进阶搜寻


    jsp.display-item.identifier=請使用永久網址來引用或連結此文件: https://ir.csmu.edu.tw:8080/ir/handle/310902500/24865


    题名: Pioglitazone Exposure Reduced the Risk of All-Cause Mortality in Insulin-Treated Patients with Type 2 Diabetes Mellitus
    作者: Yen, FS;Wang, HC;Pan, CW;Wei, JCC;Hsu, CC;Hwu, CM
    关键词: type 2 diabetes mellitus;insulin;pioglitazone;therapeutics;mortality
    日期: 2020
    上传时间: 2022-08-09T08:09:16Z (UTC)
    出版者: ENDOCRINE SOC
    ISSN: 0021-972X
    摘要: Context: The long-term safety and benefit of pioglitazone use in combination with insulin are still uncertain. Objective: This study compared the risks of all-cause mortality and major cardiovascular (CV) events between pioglitazone users and nonusers receiving insulin therapy. Design, Setting and Patients: We conducted a 13-year retrospective cohort study by using data from the population-based National Health Insurance Research Database in Taiwan. A total of 20 376 patients with type 2 diabetes mellitus (T2DM) receiving insulin therapy were enrolled during 2000 to 2012. Overall, the incidence rates of all-cause mortality and CV events were compared between 2579 pioglitazone users and 2579 matched nonusers. Results: After adjustment for age, sex, comorbidities, Diabetes Complications Severity Index scores, and drugs used, mortality rates were 30.26 and 15.02 per 1000 person-years for pioglitazone nonusers and users, respectively. The adjusted hazard ratio (aHR) of mortality was 0.47 (95% confidence interval [CI]: 0.38-0.58, P < 0.001) for pioglitazone users compared with nonusers. The aHRs of CV and non-CV deaths were 0.78 (95% CI: 0.51-1.19) and 0.50 (95% CI: 0.38-0.66), respectively. The aHRs of hospitalized coronary artery disease, hospitalized stroke, and incident heart failure were not significantly different between pioglitazone users and nonusers. Conclusions: This nationwide cohort study demonstrated that pioglitazone use reduced the risks of all-cause mortality and non-CV death for patients with T2DM undergoing insulin therapy.
    URI: http://dx.doi.org/10.1210/clinem/dgz026
    https://www.webofscience.com/wos/woscc/full-record/WOS:000525870500040
    https://ir.csmu.edu.tw:8080/handle/310902500/24865
    關聯: JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM ,2020 ,v105 ,issue 3 E401-E409
    显示于类别:[中山醫學大學研究成果] 期刊論文

    文件中的档案:

    档案 描述 大小格式浏览次数
    index.html0KbHTML193检视/开启


    SFX Query

    在CSMUIR中所有的数据项都受到原著作权保护.

    TAIR相关文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回馈